Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Scilex Holding Company (SCLX : NSDQ)

• Company Description    Scilex Holding Company is a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain. Scilex Holding Company, formerly known as Vickers Vantage Corp. I, is based in PALO ALTO, Calif. Number of Employees: 34

• Price / Volume Information    Yesterday's Closing Price: $6.11 Daily Weekly Monthly 20 Day Moving Average: 100,710 shares Shares Outstanding: 8.49 (millions) Market Capitalization: $51.88 (millions) Beta: 1.77 52 Week High: $34.27 52 Week Low: $4.43 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -11.96% -16.26% 12 Week -24.75% -30.44% Year To Date -49.92% -55.39%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 960 SAN ANTONIO ROAD - PALO ALTO,CA 94303 USA ph: 650-516-4310 fax: - investorrelations@scilexholding.com http://www.scilexholding.com

• General Corporate Information    Officers Henry Ji - Chief Executive Officer; President; Chairperson an Stephen Ma - Chief Financial Officer; Chief Operating Officer; Dorman Followwill - Director Jay Chun - Director Yue Alexander - Director Peer Information Scilex Holding Company (CORR.) Scilex Holding Company (RSPI) Scilex Holding Company (CGXP) Scilex Holding Company (BGEN) Scilex Holding Company (GTBP) Scilex Holding Company (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 80880W205 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/12/26 Share - Related Items Shares Outstanding: 8.49 Most Recent Split Date: 4.00 (0.03:1) Beta: 1.77 Market Capitalization: $51.88 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/12/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 1.53 EPS Growth vs. Year Ago Period: -110.62% vs. Previous Quarter: -3.48% Sales Growth vs. Year Ago Period: 72.12% vs. Previous Quarter: 79.70% ROE 03/31/26 - - 12/31/25 - - 09/30/25 - - ROA 03/31/26 - -143.55 12/31/25 - -178.57 09/30/25 - -249.89 Current Ratio 03/31/26 - 0.08 12/31/25 - 0.08 09/30/25 - 0.05 Quick Ratio 03/31/26 - - 12/31/25 - 0.07 09/30/25 - 0.04 Operating Margin 03/31/26 - -1,079.14 12/31/25 - -1,185.78 09/30/25 - -822.80 Net Margin 03/31/26 - -1,110.17 12/31/25 - -1,185.78 09/30/25 - -822.80 Pre-Tax Margin 03/31/26 - -1,162.36 12/31/25 - -1,236.33 09/30/25 - -828.52 Book Value 03/31/26 - -29.92 12/31/25 - -24.94 09/30/25 - -23.69 Inventory Turnover 03/31/26 - 4.23 12/31/25 - 3.72 09/30/25 - 5.60 Debt-to-Equity 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Capital 03/31/26 - - 12/31/25 - - 09/30/25 - -

Powered by Zacks Investment Research ©